



HYBRID
FORMAT

IV Workshop on
**GENOMIC
TESTING IN
CANCER**
FACING A NEW ERA IN
PERSONALIZED MEDICINE


OCTOBER, 27th-29th, 2021




Organized by



www.cun.es/genomicscancer



Sign up 



IV Workshop on
GENOMIC TESTING IN CANCER
 FACING A NEW ERA IN PERSONALIZED MEDICINE

HYBRID FORMAT

OCTOBER, 27th-29th, 2021

WEDNESDAY, OCTOBER 27th

15:30 - 16:00

Welcome

Jesús San Miguel

Head of Clinical and Translational Medicine, Clínica Universidad de Navarra Pamplona, Spain

Ignacio Gil-Bazo

Co-Chair, IV International Workshop, Clínica Universidad de Navarra and CIMA, Pamplona, Spain

Antonio González

Co-Chair, IV International Workshop, Clínica Universidad de Navarra Madrid, Spain

16:05 - 17:55

SESSION I SINGLE-CELL TECHNOLOGIES IN CANCER TESTING

Chairs

Miguel F. Sanmamed

Clínica Universidad de Navarra and CIMA, Pamplona, Spain

Gorka Alkorta

CIMA LAB Diagnostics, Universidad de Navarra, Pamplona, Spain

16:05 - 16:35

Single-molecule sequencing

Iñigo Martincorena

Sanger Institute, Cambridge, UK

16:35 - 17:05

Novel radioligand and radiotracer development for various targets involved in cancer

Corinne Beinat

Stanford University, California, USA

17:05 - 17:35

Single cell proteomics and cancer Immunotherapy

Matthew Spitzer

UCSF, San Francisco, USA

17:35 - 17:55

Discussion

17:55 - 18:10

Pause

18:10 - 19:10

Keynote Session

Chairs

Luis Montuenga

Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain


Álvaro González

Clínica Universidad de Navarra, Pamplona, Spain

Genomic testing as a key tool in precision medicine

Mariano Barbacid

CNIO, Madrid, Spain



IV Workshop on
GENOMIC TESTING IN CANCER
FACING A NEW ERA IN PERSONALIZED MEDICINE

HYBRID FORMAT

OCTOBER, 27th-29th, 2021

THURSDAY, OCTOBER 28th

15:00 - 16:50 SESSION II **BIOMARKERS OF RESISTANCE TO TARGETED THERAPIES**

Chairs

Julián Sanz

Clínica Universidad de Navarra, Madrid, Spain

Antonio González

Clínica Universidad de Navarra, Madrid, Spain

15:00 - 15:30

Liquid biopsy in the identification of resistance to targeted therapy

Christian Rolfo

Mount Sinai Cancer Center, New York, USA

15:30 - 16:00

Molecular determinants of response and resistance to PARP inhibitors

Iain McNeish

Imperial college, London, UK

16:00 - 16:30

NRG1 fusions as predictors of response to Zenocutuzumab: eNergy Trial

Alison Schram

Memorial Sloan Kettering Cancer Center, New York, USA.

16:30 - 16:50

Discussion

16:50 - 17:05

Pause

17:05 - 18:25 SESSION III **ARTIFICIAL INTELLIGENCE AND BIG DATA IN CANCER GENOMICS**

Chairs

Mikel Hernáez

CIMA, Universidad de Navarra, Pamplona, Spain

Josep María Argemí

Clínica Universidad de Navarra and CIMA, Universidad de Navarra, Pamplona, Spain

17:05 - 17:35

A meta-learning approach for genomic survival analysis in cancer

Olivier Gevaert

Stanford University, California, USA

17:35 - 18:05

The use of large-scale cancer genomics to identify new potential targets

Raúl Rabadán

Columbia University, New York, USA

18:05 - 18:25

Discussion

18:25 - 18:40

Pause

18:40 - 20:00 SESSION IV **CANCER EPIGENOMICS**

Chairs

María José Calasanz

CIMA, Universidad de Navarra, Pamplona, Spain

Ignacio Gil-Bazo

Clínica Universidad de Navarra, Pamplona, Spain

18:40 - 19:10

Are cancer epigenomics ready for primetime?

Manel Esteller

Josep Carreras Leukaemia Research Institute, Barcelona, Spain

19:10 - 19:40

Clinical trials targeting epigenetics for cancer therapy: what's new?

Diego L. Cortinovis

Azienda Socio Sanitaria Territoriale di Monza, Italy.


19:40 - 20:00

Discussion

IV Workshop on
GENOMIC TESTING IN CANCER
FACING A NEW ERA IN PERSONALIZED MEDICINE

HYBRID FORMAT

OCTOBER, 27th-29th, 2021



FRIDAY, OCTOBER 29th

15:00 - 17:20 **SESSION V BIOMARKERS OF RESISTANCE TO IMMUNOTHERAPY**

Chairs

Rubén Pío

CIMA, Universidad de Navarra, Pamplona, Spain

Ignacio Melero

Clínica Universidad de Navarra and CIMA, Pamplona, Spain

15:00 - 15:30

Sensitivity and resistance determinants in genitourinary tumors

Thomas Powles

Barts Cancer Center, London, UK

15:30 - 16:00

TMB, PD-L1 and beyond as predictive biomarkers in immunotherapy

Luis Ráez

Memorial Cancer Institute, Miami, USA

16:00 - 16:30

The immune landscape of lung cancer

Ignacio I. Wistuba

University of Texas, MD Anderson Cancer Center, Houston, USA

16:30 - 17:00

Gut microbiome and immune checkpoint inhibitors efficacy

Bertrand Routy


University of Montreal, Canada

17:00 - 17:20

Discussion

17:20 - 17:35

Pause



17:35 - 19:55 **SESSION VI ADVANCED THERAPIES AGAINST CANCER**

Chairs

Ana Patiño

Clínica Universidad de Navarra and CIMA, Pamplona, Spain

Mariano Ponz-Sarvisé

Clínica Universidad de Navarra, Pamplona, Spain

17:35 - 18:05

CAR T-cell therapy against solid tumors

Marcela Maus

Massachusetts General Cancer Center, Boston, USA

18:05 - 18:35

Proton beam radiotherapy in the precision medicine era

Felipe Calvo

Clínica Universidad de Navarra, Madrid, Spain

18:35 - 19:05

The use of organoids in cancer therapy

David Tuveson

Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, USA

19:05 - 19:35

Challenges of BiTEs in cancer treatment

Elena Garralda

VHIO, Barcelona, Spain

19:35 - 19:55

Discussion

19:55 - 20:05

CLOSING REMARKS

Antonio González

Clínica Universidad de Navarra, Madrid, Spain

Ignacio Gil-Bazo

Clínica Universidad de Navarra, Pamplona, Spain



Clínica
Universidad
de Navarra

Organized by



cima
CENTRO DE INVESTIGACIÓN
MÉDICA APLICADA
UNIVERSIDAD DE NAVARRA



IdiSNA
INSTITUTO DE INVESTIGACIÓN
SANITARIA DE NAVARRA

Accreditation

An application has been made to the Navarre Healthcare
Professional Continuing Education Commission (Spain)

Workshop Secretariat



Tel.: (+34) 91 372 02 03
e-mail: genomicscancer@doctaforum.com